BXOS110 Injection Phase III Acute Ischaemic Stroke Trial
Summary
The National Library of Medicine registered a Phase III clinical trial (NCT07520565) evaluating BXOS110 Injection for acute ischaemic stroke. The trial appears to be investigating a novel therapeutic intervention. ClinicalTrials.gov serves as the public registry for clinical trials required under FDA regulations.
What changed
The National Library of Medicine added a new clinical trial registration for BXOS110 Injection, a Phase III study targeting acute ischaemic stroke patients. The trial is now publicly listed on ClinicalTrials.gov with identifier NCT07520565.
Affected parties including clinical investigators, trial sponsors, and healthcare providers should monitor this trial for enrollment updates and potential implications for stroke treatment protocols. Pharmaceutical and biotechnology companies developing competing stroke therapies may wish to track this trial's progress.
What to do next
- Monitor trial progress on ClinicalTrials.gov
- Review inclusion/exclusion criteria for potential enrollment
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.